Conexeu Sciences Inc. has reported a milestone in regenerative medicine with the creation of the first 3D-printed tissue structures from its patented functional extracellular matrix (ECM).
While the company is awaiting FDA clearance before introducing the technology into clinical settings such as aesthetics, wound healing, and reconstructive surgery, Conexeu has successfully printed bovine-derived, collagen-based scaffolds using its CXU™ bioink platform. The process uses 3D bioprinting, which allows for precise layering of cells to control the structure and shape of the final product.
Opening the Door
“By showing that CXU can print tissue structures, we are opening the door to truly personalized implants and grafts,” said Conexeu’s chief science officer, Claudia Chavez-Munoz, MD, PhD. “If cleared by the FDA, this will place CXU at the forefront of all bioinks, being the first collagen-based extracellular matrix medical grade in the market.”
The company plans to focus on three domains:
- Personalized implants and grafts
- Vascular-supportive microenvironments
- Biofabrication in medicine
The CXU collagen platform, an extracellular matrix, will be used as a foundation for personalized tissue regeneration in the future. Personalization will involve craniofacial, breast, periodontal and soft-tissue reconstruction, printed to match the patient.
Vascular-supportive microenvironments are designed to support neovascularization, a key factor in long-term viability and function of regenerated tissue. By providing the scaffolding that helps new blood vessels grow, CXU may help sustain cellular survival and activity following implantation. If cleared for commercialization, the platform could have relevance in wound care, aesthetics, dental, reconstructive surgery, and 3D bioprinting.
CXU is being developed as both an injectable regenerative device and a printable ECM bioink, providing a single united platform for biofabrication, the automated generation of complex biological products from living cells, bioactive molecules, and biomaterials. The use of 3D bioprinting to create an implantable ECM that supports vascularization beneath the skin may be particularly relevant for regenerative and reconstructive applications.
Looking to the Future
In October 2025, Conexeu completed a $5 million Regulation Crowdfunding financing, reaching the maximum amount permitted within a 12-month period. The funds are being used to accelerate the development and commercialization of the CXU collagen platform and position the company to enter the estimated $17.4B addressable market. The global bioprinting market alone is projected to exceed $6B by 2032.
By demonstrating CXU’s ability to print tissue structures, Conexeu is positioning itself as a potential trailblazer in the field of aesthetics and tissue reconstruction. Pending FDA clearance, the technology may represent a meaningful advancement in medical-grade bioinks for tissue regeneration and reconstruction.
